Form 8-K - Current report:
SEC Accession No. 0001104659-20-056552
Filing Date
2020-05-05
Accepted
2020-05-05 08:35:54
Documents
15
Period of Report
2020-05-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2018517d1_8k.htm 8-K 18849
2 EXHIBIT 99.1 tm2018517d1_ex99-1.htm EX-99.1 8654
3 EXHIBIT 99.2 tm2018517d1_ex99-2.htm EX-99.2 12257
4 GRAPHIC image_001.gif GRAPHIC 2678
5 GRAPHIC image_001.jpg GRAPHIC 88831
6 GRAPHIC image_002.jpg GRAPHIC 78665
7 GRAPHIC image_003.jpg GRAPHIC 84206
8 GRAPHIC image_004.jpg GRAPHIC 76789
9 GRAPHIC image_005.jpg GRAPHIC 74771
10 GRAPHIC image_006.jpg GRAPHIC 81356
11 GRAPHIC image_007.jpg GRAPHIC 70434
12 GRAPHIC image_008.jpg GRAPHIC 80759
13 GRAPHIC image_009.jpg GRAPHIC 79462
14 GRAPHIC image_010.jpg GRAPHIC 67664
15 GRAPHIC image_011.jpg GRAPHIC 63179
  Complete submission text file 0001104659-20-056552.txt   1205867
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 20847049
SIC: 2834 Pharmaceutical Preparations